(Q30835288)

27 June 2017

title

rhDNase therapy for the treatment of cystic fibrosis patients with mild to moderate lung disease (English)

1 reference

27 June 2017

0 references

Christopher F

1

1 reference

27 June 2017

Chase D

series ordinal

2

1 reference

27 June 2017

Stein K

series ordinal

3

1 reference

27 June 2017

Milne R

series ordinal

4

1 reference

27 June 2017

publication date

1 December 1999

1 reference

Journal of Clinical Pharmacy and Therapeutics

27 June 2017

published in

1 reference

27 June 2017

volume

24

1 reference

27 June 2017

issue

6

1 reference

27 June 2017

page(s)

415-426

1 reference

Incidence, population, and survival of cystic fibrosis in the UK, 1968-95. UK Cystic Fibrosis Survey Management Committee

27 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.1999.00245.X

Management of pulmonary disease in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.1999.00245.X

Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.1999.00245.X

Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.1999.00245.X

Medium term treatment of stable stage cystic fibrosis with recombinant human DNase I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.1999.00245.X

DNase in cystic fibrosis: the challenge of assessing response and maximising benefit

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.1999.00245.X

Retrospective review of the effects of rhDNase in children with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.1999.00245.X

Effect of high-dose ibuprofen in patients with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2710.1999.00245.X

10.1046/J.1365-2710.1999.00245.X

21 January 2018

Identifiers

DOI

1 reference

release_y2umg2nwljfwpfl73hhe5qrtrq

27 June 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/y2umg2nwljfwpfl73hhe5qrtrq

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference